Fabricate Tunable Terahertz Magnon Laser to eradicate cancer

Hi, my name is Boris G Tankhilevich, I have Ph. D. in quantum magnetism, I am also a registered US Patent Attorney with many years of successful patent practice before USPTO. I obtained about 200 US Patents for my clients.

I invented the revolutionary new device -Tunable Terahertz Magnon Laser that can be used to treat cancer without any side effects.

I also started the company - Magtera to facilitate the development and applications of the Tunable Terahertz Magnon Laser. This technology is well protected by 22 US Patents.

The prototype of this device was fabricated in UC Santa Barbara, and the proof of principle was demonstrated in the Institute for Terahertz Science and Technology located at UC Santa Barbara.

This new method of cancer treatment was published in the peer-reviewed journal- please, see Tankhilevich, B. G. (2023). Novel Terahertz-Based Radiation Treatment of Cancer Without Side Effects. J Pharma Res Dev., 4(2): 1-3. DOI : https://doi.org/10.47485/2694-5614.1022

I was also invited to do the presentation at the 16-th Annual World Cancer Congress, June 12-14, 2024, Budapest, Hungary. https://www.bitcongress.com/cancer2024/contactus.asp

All current methods of Cancer treatments can cause side effects.

The Tunable Terahertz Magnon Laser Novel Approach- is treatment of cancer without side effects.

This new method should work for all types of cancer and for all stages of cancer.

The eradication of cancer is very important for me as it is the next step in the progress of humanity following the eradication of polio, treatment for tuberculosis, etc.

I raise funds to fabricate the actual device and to satisfy the FDA requirements.

Indeed, FDA regulates medical lasers as Class IV devices and the manufacturer should be registered with FDA. and do one or two pilot clinical trials. The budget for prototyping and a pilot clinical trial in cancer patients may be 2 million, depending on the cost of optimizing the device for cancer therapy and setting up manufacturing in compliance with FDA regulations as well as the complexity of clinical study parameters.